NON-HODGEKIN LYMPHOMA (NHL-BOTH FOLLICULAR & DIFFUSE LARGE CELL)

Clinical trials for NON-HODGEKIN LYMPHOMA (NHL-BOTH FOLLICULAR & DIFFUSE LARGE CELL) explained in plain language.

Never miss a new study

Get alerted when new NON-HODGEKIN LYMPHOMA (NHL-BOTH FOLLICULAR & DIFFUSE LARGE CELL) trials appear

Sign up with your email to follow new studies for NON-HODGEKIN LYMPHOMA (NHL-BOTH FOLLICULAR & DIFFUSE LARGE CELL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New CAR T-Cell therapy targets Hard-to-Treat blood cancers

Disease control Not yet recruiting

This study tests a new treatment called SHB-02-CD19 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer …

Matched conditions: NON-HODGEKIN LYMPHOMA (NHL-BOTH FOLLICULAR & DIFFUSE LARGE CELL)

Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control

Last updated May 01, 2026 15:59 UTC

NON-HODGEKIN LYMPHOMA (NHL-BOTH FOLLICULAR & DIFFUSE LARGE CELL)

Get alerted when new NON-HODGEKIN LYMPHOMA (NHL-BOTH FOLLICULAR & DIFFUSE LARGE CELL) trials appear

New CAR T-Cell therapy targets Hard-to-Treat blood cancers